NYSE:LLY - Eli Lilly And Co Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$86.07 -0.21 (-0.24 %)
(As of 06/22/2018 03:26 AM ET)
Previous Close$86.28
Today's Range$85.19 - $86.28
52-Week Range$73.69 - $89.09
Volume2.86 million shs
Average Volume4.44 million shs
Market Capitalization$94.24 billion
P/E Ratio20.11
Dividend Yield2.59%
Beta0.29
Eli Lilly And Co logoEli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics, as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:LLY
CUSIP53245710
Phone317-276-2000

Debt

Debt-to-Equity Ratio0.64
Current Ratio1.41
Quick Ratio1.01

Price-To-Earnings

Trailing P/E Ratio20.11
Forward P/E Ratio16.71
P/E Growth1.47

Sales & Book Value

Annual Sales$22.87 billion
Price / Sales4.08
Cash Flow$5.4892 per share
Price / Cash15.68
Book Value$10.60 per share
Price / Book8.12

Profitability

EPS (Most Recent Fiscal Year)$4.28
Net Income$-204,100,000.00
Net Margins4.82%
Return on Equity35.37%
Return on Assets11.30%

Miscellaneous

Employees40,655
Outstanding Shares1,085,430,000

Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions

What is Eli Lilly And Co's stock symbol?

Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?

Eli Lilly And Co declared a quarterly dividend on Monday, June 18th. Stockholders of record on Wednesday, August 15th will be given a dividend of $0.5625 per share on Monday, September 10th. This represents a $2.25 annualized dividend and a dividend yield of 2.61%. The ex-dividend date is Tuesday, August 14th. View Eli Lilly And Co's Dividend History.

How were Eli Lilly And Co's earnings last quarter?

Eli Lilly And Co (NYSE:LLY) posted its quarterly earnings data on Tuesday, April, 24th. The company reported $1.34 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.13 by $0.21. The firm had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.51 billion. Eli Lilly And Co had a net margin of 4.82% and a return on equity of 35.37%. Eli Lilly And Co's revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.98 earnings per share. View Eli Lilly And Co's Earnings History.

When is Eli Lilly And Co's next earnings date?

Eli Lilly And Co is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Eli Lilly And Co.

What guidance has Eli Lilly And Co issued on next quarter's earnings?

Eli Lilly And Co issued an update on its FY18 earnings guidance on Tuesday, April, 24th. The company provided EPS guidance of $5.10-5.20 for the period, compared to the Thomson Reuters consensus estimate of $4.87. The company issued revenue guidance of $23.7-24.2 billion, compared to the consensus revenue estimate of $23.43 billion.

What price target have analysts set for LLY?

19 brokers have issued 12 month target prices for Eli Lilly And Co's shares. Their forecasts range from $78.00 to $115.00. On average, they anticipate Eli Lilly And Co's stock price to reach $94.0556 in the next year. View Analyst Ratings for Eli Lilly And Co.

Who are some of Eli Lilly And Co's key competitors?

Who are Eli Lilly And Co's key executives?

Eli Lilly And Co's management team includes the folowing people:
  • Mr. David A. Ricks, Chairman, CEO & Pres (Age 50)
  • Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 55)
  • Mr. Enrique A. Conterno, Sr. VP (Age 51)
  • Mr. Joshua L. Smiley, Sr. VP & CFO (Age 48)
  • Mr. Donald A. Zakrowski, Chief Accounting Officer and VP of Fin.

Has Eli Lilly And Co been receiving favorable news coverage?

Media stories about LLY stock have been trending positive recently, Accern reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eli Lilly And Co earned a news impact score of 0.26 on Accern's scale. They also gave headlines about the company an impact score of 46.39 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Eli Lilly And Co's major shareholders?

Eli Lilly And Co's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.06%), Franklin Resources Inc. (3.00%), Northern Trust Corp (1.04%), Massachusetts Financial Services Co. MA (0.73%), Legal & General Group Plc (0.43%) and Schroder Investment Management Group (0.43%). Company insiders that own Eli Lilly And Co stock include Alfonso G Zulueta, Christi Shaw, Daniel Skovronsky, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.

Which institutional investors are selling Eli Lilly And Co stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Neuberger Berman Group LLC, Amundi Pioneer Asset Management Inc., Sei Investments Co., Northern Trust Corp, Massachusetts Financial Services Co. MA, Swiss National Bank and Eaton Vance Management. Company insiders that have sold Eli Lilly And Co company stock in the last year include Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Enrique A Conterno, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc and Susan Mahony. View Insider Buying and Selling for Eli Lilly And Co.

Which institutional investors are buying Eli Lilly And Co stock?

LLY stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Schroder Investment Management Group, BlackRock Inc., LSV Asset Management, Alps Advisors Inc., Mackay Shields LLC, Point72 Asset Management L.P. and Summit Trail Advisors LLC. Company insiders that have bought Eli Lilly And Co stock in the last two years include Daniel Skovronsky, Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly And Co.

How do I buy shares of Eli Lilly And Co?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly And Co's stock price today?

One share of LLY stock can currently be purchased for approximately $86.07.

How big of a company is Eli Lilly And Co?

Eli Lilly And Co has a market capitalization of $94.24 billion and generates $22.87 billion in revenue each year. The company earns $-204,100,000.00 in net income (profit) each year or $4.28 on an earnings per share basis. Eli Lilly And Co employs 40,655 workers across the globe.

How can I contact Eli Lilly And Co?

Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]


MarketBeat Community Rating for Eli Lilly And Co (LLY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  780 (Vote Outperform)
Underperform Votes:  617 (Vote Underperform)
Total Votes:  1,397
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.